CYP17MspA1 Polymorphism and Age at Menarche: A Meta-Analysis

Objective: Literature data on the effects ofCYP17 MspA1 polymorphism on age at menarche (AAM) are inconsistent. To reexamine this controversy, we performed a meta-analysis.Study design: In total 16 studies containing more than 11000 individuals of various ethnicities were selected for the analyses. For 11 case-control studies, odds ratio (OR) was employed to evaluate the risk of late AAM for each study, using homozygote at the wild-type allele as a control group. For the 5 studies with continuous outcomes, the effect size was estimated using the Hedges’ adjusted g, which is calculated based on the standardized mean difference between groups of subjects with early and late AAM.Results: We did not find evidence for association of the MspA1 polymorphism with AAM in the combined case-control sample with mixed ethnic background (OR = 1.03, 95% CI: 0.90–1.18,P= 0.66), in the monoethnic case-control sample of Caucasian females (OR = 1.09, 95% CI: 0.99–1.20,P= 0.08) and in the combined sample with continuous traits (Hedges’ g = 0.33 and −0.041, 95% CI: −0.14–0.80 and −0.18–0.10,Pvalues 0.17 and 0.56 for the pooled population sample and monoethnic sample of Caucasian females, respectively).Conclusion: Our study showed thatCYP17 MspA1 polymorphism was not a significant independent risk factor of AAM. Further studies are needed to clarify the effects of the interaction between this gene and other genetic and/or environment factors on AAM.

Download Full-text

Oral Contraceptive Use and Breast Cancer Risk Assessment: A Systematic Review and Meta-Analysis of Case-Control Studies, 2009–2020

Cancers ◽

10.3390/cancers13225654 ◽

2021 ◽

Vol 13 (22) ◽

pp. 5654

Author(s):

Agnieszka Barańska ◽

Agata Błaszczuk ◽

Wiesław Kanadys ◽

Maria Malm ◽

Katarzyna Drop ◽

...

Keyword(s):

Breast Cancer ◽

Oral Contraceptive ◽

Cancer Risk ◽

Meta Analysis ◽

Case Control ◽

Cochrane Library ◽

Control Group ◽

Case Control Studies ◽

Increased Risk ◽

Breast Cancer Risk Assessment

To perform a meta-analysis of case-control studies that addressed the association between oral contraceptive pills (OC) use and breast cancer (BrCa), PubMED (MEDLINE), Embase, and the Cochrane Library were searched to identify case-control studies of OC and BrCa published between 2009 and 2020. We used the DerSimonian–Laird method to compute pooled odds ratios (ORs) and confidence intervals (CIs), and the Mantel–Haenszel test to assess the association between OC use and cancer. Forty-two studies were identified that met the inclusion criteria and we included a total of 110,580 women (30,778 into the BrCa group and 79,802 into the control group, of which 15,722 and 38,334 were using OC, respectively). The conducted meta-analysis showed that the use of OC was associated with a significantly increased risk of BrCa in general, OR = 1.15, 95% CI: 1.01 to 1.31, p = 0.0358. Regarding other risk factors for BrCa, we found that increased risk was associated significantly with early menarche, nulliparous, non-breastfeeding, older age at first parity, postmenopause, obesity, smoking, and family history of BrCa. Despite our conclusion that birth control pills increase the cancer risk being supported by extensive previous studies and meta-analyzes, further confirmation is required.

Download Full-text

Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis

F1000Research ◽

10.12688/f1000research.16758.2 ◽

2019 ◽

Vol 7 ◽

pp. 1725 ◽

Cited By ~ 1

Author(s):

Carl Heneghan ◽

Jeffrey K. Aronson ◽

Elizabeth Spencer ◽

Bennett Holman ◽

Kamal R. Mahtani ◽

...

Keyword(s):

Systematic Review ◽

Cohort Studies ◽

Congenital Malformations ◽

Meta Analysis ◽

Case Control ◽

Control Group ◽

Case Control Studies ◽

Renal Anomalies ◽

Congenital Heart Malformations ◽

Increased Risk

Background: Oral hormone pregnancy tests (HPTs), such as Primodos, containing ethinylestradiol and high doses of norethisterone, were given to over a million women from 1958 to 1978, when Primodos was withdrawn from the market because of concerns about possible teratogenicity. We aimed to study the association between maternal exposure to oral HPTs and congenital malformations. Methods: We have performed a systematic review and meta-analysis of case-control and cohort studies that included data from pregnant women and were exposed to oral HPTs within the estimated first three months of pregnancy, if compared with a relevant control group. We used random-effects meta-analysis and assessed the quality of each study using the Newcastle–Ottawa Scale for non-randomized studies. Results: We found 16 case control studies and 10 prospective cohort studies, together including 71 330 women, of whom 4,209 were exposed to HPTs. Exposure to oral HPTs was associated with a 40% increased risk of all congenital malformations: pooled odds ratio (OR) = 1.40 (95% CI 1.18 to 1.66; P<0.0001; I2 = 0%). Exposure to HPTs was associated with an increased risk of congenital heart malformations: pooled OR = 1.89 (95% CI 1.32 to 2.72; P = 0.0006; I2=0%); nervous system malformations OR = 2.98 (95% CI 1.32 to 6.76; P = 0.0109 I2 = 78%); gastrointestinal malformations, OR = 4.50 (95% CI 0.63 to 32.20; P = 0.13; I2 = 54%); musculoskeletal malformations, OR = 2.24 (95% CI 1.23 to 4.08; P= 0.009; I2 = 0%); the VACTERL syndrome (Vertebral defects, Anal atresia, Cardiovascular anomalies, Tracheoesophageal fistula, Esophageal atresia, Renal anomalies, and Limb defects), OR = 7.47 (95% CI 2.92 to 19.07; P < 0.0001; I2 = 0%). Conclusions: This systematic review and meta-analysis shows that use of oral HPTs in pregnancy is associated with increased risks of congenital malformations.

Download Full-text

Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies

Fertility and Sterility ◽

10.1016/j.fertnstert.2012.05.035 ◽

2012 ◽

Vol 98 (3) ◽

pp. 702-712.e6 ◽

Cited By ~ 59

Author(s):

Kelechi E. Nnoaham ◽

Premila Webster ◽

Jharna Kumbang ◽

Stephen H. Kennedy ◽

Krina T. Zondervan

Keyword(s):

Systematic Review ◽

Risk Factor ◽

Meta Analysis ◽

Case Control ◽

Age At Menarche ◽

Early Age ◽

Case Control Studies

Download Full-text

Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis

F1000Research ◽

10.12688/f1000research.16758.1 ◽

2018 ◽

Vol 7 ◽

pp. 1725 ◽

Cited By ~ 1

Author(s):

Carl Heneghan ◽

Jeffrey K. Aronson ◽

Elizabeth Spencer ◽

Bennett Holman ◽

Kamal R. Mahtani ◽

...

Keyword(s):

Systematic Review ◽

Cohort Studies ◽

Congenital Malformations ◽

Meta Analysis ◽

Case Control ◽

Control Group ◽

Case Control Studies ◽

Renal Anomalies ◽

Congenital Heart Malformations ◽

Increased Risk

Background: Oral hormone pregnancy tests (HPTs), such as Primodos, containing ethinylestradiol and high doses of norethisterone, were given to over a million women from 1958 to 1978, when Primodos was withdrawn from the market because of concerns about possible teratogenicity. We aimed to study the association between maternal exposure to oral HPTs and congenital malformations. Methods: We have performed a systematic review and meta-analysis of case-control and cohort studies that included data from pregnant women and were exposed to oral HPTs within the estimated first three months of pregnancy, if compared with a relevant control group. We used random-effects meta-analysis and assessed the quality of each study using the Newcastle–Ottawa Scale for non-randomized studies. Results: We found 16 case control studies and 10 prospective cohort studies, together including 71 330 women, of whom 4209 were exposed to HPTs. Exposure to oral HPTs was associated with a 40% increased risk of all congenital malformations: pooled odds ratio (OR) = 1.40 (95% CI 1.18 to 1.66; P<0.0001; I2 = 0%). Exposure to HPTs was associated with an increased risk of congenital heart malformations: pooled OR = 1.89 (95% CI 1.32 to 2.72; P = 0.0006; I2=0%); nervous system malformations OR = 2.98 (95% CI 1.32 to 6.76; P = 0.0109 I2 = 78%); gastrointestinal malformations, OR = 4.50 (95% CI 0.63 to 32.20; P = 0.13; I2 = 54%); musculoskeletal malformations, OR = 2.24 (95% CI 1.23 to 4.08; P= 0.009; I2 = 0%); the VACTERL syndrome (Vertebral defects, Anal atresia, Cardiovascular anomalies, Tracheoesophageal fistula, Esophageal atresia, Renal anomalies, and Limb defects), OR = 7.47 (95% CI 2.92 to 19.07; P < 0.0001; I2 = 0%). Conclusions: This systematic review and meta-analysis shows that use of oral HPTs in pregnancy is associated with increased risks of congenital malformations.

Download Full-text

The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors

Thrombosis and Haemostasis ◽

10.1160/th07-11-0658 ◽

2008 ◽

Vol 99 (11) ◽

pp. 925-929 ◽

Cited By ~ 44

Author(s):

Matus Rehak ◽

Jiri Rehak ◽

Marc Müller ◽

Susanne Faude ◽

Frank Faude ◽

...

Keyword(s):

Risk Factors ◽

Retinal Vein Occlusion ◽

Meta Analysis ◽

Factor V Leiden ◽

Case Control ◽

Control Group ◽

Factor V ◽

Case Control Studies ◽

Apc Resistance ◽

Vein Occlusion

SummarySeveral small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62–3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19–2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.

Download Full-text

Gene Polymorphism and Precocious Puberty: A Meta-Analysis of Case-Control Studies

Advanced Materials Research ◽

10.4028/www.scientific.net/amr.647.466 ◽

2013 ◽

Vol 647 ◽

pp. 466-470 ◽

Cited By ~ 1

Author(s):

Min Jie Zhang ◽

Zong Lin Gong ◽

Di Han ◽

Xiang Gao ◽

Qi Tan ◽

...

Keyword(s):

Gene Polymorphism ◽

Precocious Puberty ◽

Independent Risk Factor ◽

Meta Analysis ◽

Control Sample ◽

Case Control ◽

Case Control Studies ◽

China National Knowledge Infrastructure ◽

Medline Search ◽

Knowledge Infrastructure

Objective: To reexamine literature and data on the effects of gene polymorphism on precocious puberty via a meta-analysis. Methods: Consultation of search engines Chinese Bio-medicine Database, China National Knowledge Infrastructure, Pubmed and Medline search resulted in a total of seven studies containing more than 4300 individuals from various ethnic backgrounds. To evaluate the risk of precocious puberty, odds ratios (OR) for all case-control studies were calculated. Results: In this meta-analysis no significant association of the gene polymorphism with precocious puberty in the combined case-control sample (OR=1.19, 95%CI: 0.88-1.62, P=0.26) was found. Conclusion: This study found no evidence of gene polymorphism being an independent risk factor of precocious puberty. Further studies are needed further understand the effects of the interactions between these genes and other genetic and/or environment factors on precocious puberty.

Download Full-text

Association Between Apolipoprotein Gene Polymorphisms and Hyperlipidemia: A Meta-analysis

10.21203/rs.3.rs-76751/v1 ◽

2020 ◽

Author(s):

Xiao-Ning Zhao ◽

Quan Sun ◽

You-Qin Cao ◽

Xiao Ran ◽

Yu Cao

Keyword(s):

Systematic Review ◽

Gene Polymorphisms ◽

Meta Analysis ◽

Case Control ◽

Control Group ◽

Case Group ◽

Case Control Studies ◽

Quality Of Data ◽

Different Populations ◽

The Impact

Abstract Background: Hyperlipidemia plays an important role in the etiology of cardio-cerebrovascular disease. Over recent years, a number of studies have explored the impact of apolipoprotein genetic polymorphisms in hyperlipidemia, but considerable differences and uncertainty have been found in their association for different populations from different regions. Objective: To correlate apolipoprotein gene expression with hyperlipidemia through a systematic review of case-control studies. Methods: Comprehensive identification of relevant articles in Pubmed, Web of Science, ScienceDirect, CNKI, Wangfang, and VIP published to June 9, 2020. A systematic review of hyperlipidemia case-control studies was conducted to evaluate the quality of data in articles included in the review, and a meta-analysis was conducted using Stata 11 software. Results: A total of 59 articles were included, containing in total 13843 hyperlipidemia patients in the case group and 15398 healthy controls in the control group. Meta-analysis of the data indicated that APOA5-1131T>C, APOA1 -75bp, APOB XbaⅠand APOE gene polymorphisms were significantly associated with hyperlipidemia, with OR values of 1.996, 1.228, 1.444 and 1.710, respectively, for allele models. All P values were less than 0.05. Conclusions: Meta-analysis of the data indicated that the C allele of APOA5 1131T>C, the A allele at APOA1-75bp, the APOB XbaⅠ T allele, and the ε4 allele of APOE were each a risk factor for susceptibility for hyperlipidemia.

Download Full-text